Try our beta test site

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT01079806
First received: March 2, 2010
Last updated: February 1, 2017
Last verified: December 2016
Results First Received: March 17, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Participant, Care Provider, Investigator, Outcomes Assessor;   Primary Purpose: Treatment
Condition: Chronic Hepatitis B Virus, Pediatric
Interventions: Drug: Entecavir
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Of 228 patients enrolled, 43 no longer met study criteria, 4 withdrew consent, and 1 withdrew for surgery. While the primary endpoint analysis was based on a randomized sample size of 123 participants, the overall study population was augmented to 180 to meet global regulatory requirements. All 180 randomized patients received study drug.

Reporting Groups
  Description
Entecavir Participants received entecavir, 0.015 mg/kg up to 0.5 mg, once daily, for 96 to 144 weeks, depending on response
Placebo Participants received placebo, 0 mg, once daily, for 48 to 96 weeks, depending on response

Participant Flow for 2 periods

Period 1:   Day 1 to Week 96
    Entecavir   Placebo
STARTED   120 [1]   60 [1] 
Received Treatment   120   60 
Primary Endpoint Cohort   82   41 
COMPLETED   116 [2]   56 [3] 
NOT COMPLETED   4   4 
Adverse Event                0                2 
Withdrawal by Subject                3                1 
Pregnancy                0                1 
Poor compliance or noncompliance                1                0 
[1] Randomized
[2] Includes 91 continuing treatment
[3] Includes 53 continuing treatment

Period 2:   Long-term Follow-up: Day 1-End of Study
    Entecavir   Placebo
STARTED   14   6 
COMPLETED   14   4 
NOT COMPLETED   0   2 
Withdrawal by Subject                0                2 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All participants who received study drug

Reporting Groups
  Description
Entecavir Participants received entecavir, 0.015 mg/kg up to 0.5 mg, once daily, for 96 to 144 weeks, depending on response
Placebo Participants received placebo, 0 mg, once daily, for 48 to 96 weeks, depending on response
Total Total of all reporting groups

Baseline Measures
   Entecavir   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 120   60   180 
Age 
[Units: Years]
Mean (Standard Deviation)
 10.5  (4.87)   10.8  (4.82)   10.6  (4.84) 
Age, Customized 
[Units: Participants]
     
>=2 years to <=6 years   27   14   41 
>6 years to <=12 years   31   15   46 
>12 years to <18 years   62   31   93 
Sex: Female, Male 
[Units: Participants]
Count of Participants
     
Female      42  35.0%      29  48.3%      71  39.4% 
Male      78  65.0%      31  51.7%      109  60.6% 
Ethnicity (NIH/OMB) 
[Units: Participants]
Count of Participants
     
Hispanic or Latino      2   1.7%      0   0.0%      2   1.1% 
Not Hispanic or Latino      48  40.0%      21  35.0%      69  38.3% 
Unknown or Not Reported      70  58.3%      39  65.0%      109  60.6% 
Race/Ethnicity, Customized 
[Units: Participants]
     
Asian   57   30   87 
Black/African American   14   2   16 
Native Hawaiian/Other Pacific Islander   1   0   1 
White   44   27   71 
Other   4   1   5 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Participants Who Achieved a Combination of Hepatitis B Virus (HBV) DNA Suppression and Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48   [ Time Frame: At Week 48 ]

2.  Secondary:   Percentage of Participants With Hepatitis B Virus (HBV) DNA <50 IU/mL at Week 48   [ Time Frame: At Week 48 ]

3.  Secondary:   Percentage of Participants With Hepatitis B Virus DNA <Limit of Quantitation (LOQ) at Week 48   [ Time Frame: At Week 48 ]

4.  Secondary:   Percentage of Participants With Serum Alanine Aminotransferase ≤1*Upper Limit of Normal at Week 48   [ Time Frame: At Week 48 ]

5.  Secondary:   Percentage of Participants With Hepatitis B e (HBe) Seroconversion at Week 48   [ Time Frame: At Week 48 ]

6.  Secondary:   Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Related AEs, Grade 2-4 Related AEs, Grade 3-4 AEs, Malignancies, ALT Flares, and Hepatic Disease Progression   [ Time Frame: Day 1 through Week 48 on blinded therapy ]

7.  Secondary:   Number of Participants With Laboratory Test Results Meeting the Criteria for Abnormality (Grades 1-4)   [ Time Frame: Day 1 through Week 48 on blinded therapy ]

8.  Secondary:   Number of Participants With Laboratory Test Results Meeting the Criteria for Abnormality (Grades 1-4) (Continued)   [ Time Frame: Day 1 through Week 48 on blinded therapy ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Bristol-Myers Squibb Study Director
Organization: Bristol-Myers Squibb
e-mail: Clinical.Trials@bms.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT01079806     History of Changes
Other Study ID Numbers: AI463-189 ST
Study First Received: March 2, 2010
Results First Received: March 17, 2014
Last Updated: February 1, 2017